TORONTO - FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A), a biopharmaceutical firm, announced today the submission of a Clinical Trial Application (CTA) in Australia for a Phase-1b study to evaluate the safety and efficacy of unbuzzd™, a dietary supplement aimed at enhancing alcohol metabolism. The trial, named METAL-1, will test the product on healthy volunteers in a state of alcohol intoxication.
The application is currently under review by an Australian human ethics review committee (HREC), with volunteer recruitment expected to commence in April upon approval. unbuzzd™ is a fortified oral liquid formula containing natural ingredients, vitamins, and food supplements designed to potentially improve cognition and accelerate alcohol metabolism.
Dr. Andrzej Chruscinski, FSD Pharma's Vice-President of Scientific and Clinical Affairs, expressed that the trial represents a significant effort by the company and its advisors to bring this product to market. John Duffy, CEO of Celly Nutrition, which has been developing unbuzzd™ for the U.S. consumer market, highlighted the science-based approach to the product's development and its potential cognitive benefits post-alcohol consumption.
Gerry David, retired CEO of Celsius Energy drink (Nasdaq: CELH), also conveyed optimism about the product's impact on consumers.
FSD Pharma focuses on a portfolio of innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders, including its lead compound, Lucid-MS, for multiple sclerosis. The company has licensed unbuzzd™ to Celly Nutrition Corp., with a royalty agreement on sales revenue.
This news article is based on a press release statement from FSD Pharma Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.